Results 131 to 140 of about 2,198,265 (159)

Do Extracellular Vesicles and the Biochemical Microenvironment Contribute to Amyloid Transthyretin Cardiomyopathy? [PDF]

JACC Adv
Franzini M, Greco F, Musetti V, Emdin M.
europepmc   +1 more source

Gender and Racial Distribution of Transthyretin Stabilizer Therapy in Patients With Transthyretin Cardiac Amyloidosis. [PDF]

JACC Adv
Foley SJ, Hegde S.
europepmc   +1 more source

Prevalence of amyloidosis among older cardiac patients with left ventricular hypertrophy: a cross-sectional single-centre study in Moscow, Russia. [PDF]

BMJ Open
Chernyshova T, Shchekochikhin D, Charaya K, Magomedova Z, Pandya S, Simonov A, Pershina E, Volovchenko A, Kapustina V, Myasnikov R, Andreev D.   +10 more
europepmc   +1 more source

Pathophysiology and Comprehensive Pharmacological Management of ATTR Cardiac Amyloidosis: Knowledge Gaps, Ongoing Clinical Trials, and Future Research Directions. [PDF]

Pharmaceuticals (Basel)
Bains S, Atwal H, Sidhu A, Singh H, Sodhi G.   +4 more
europepmc   +1 more source

A Hemodynamic Echocardiographic Approach to Disease Severity and Prognosis in Transthyretin Amyloid Cardiomyopathy. [PDF]

JACC Adv
Serenelli M, Cantone A, Porcari A, Pozzan M, Merlo M, Sinagra G, Guidi Colombi G, Dal Passo B, Sanguettoli F, Arzenton M, Maio D, Vitali M, Casolari G, Bonini J, Cipriani A, De Michieli L, Mele D, Sinigiani G, Tomasoni D, Metra M, Pavasini R, Biscaglia S, Campo G.   +22 more
europepmc   +1 more source